Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects.
Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.
But that wasn’t the only advance in the space as pharma...
Onduo, a Verily-Sanofi joint venture focused on digitally-driven diabetes management, is looking to further protect its members from foot ulcers and limb loss. Orpyx Medical Technologies’ diabetic foot ulcer sensors for its members.
Thanks to a newly announced deal struck between the companies, Orpyx Medical Technologies’ FDA-cleared SurroSense Rx system will be available to “select members” of...
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space.
“These technologies have a tremendous opportunity to...
Researchably, a young startup incubated at UC Berkeley, is conducting a pilot with Sanofi in China, using AI to sift through thousands of research studies and surface the most relevant ones to pharma stakeholders.
“With Sanofi we’re working with a small medical communications team, and they’re in charge of every day reviewing 100 to 200 articles on Type 2 diabetes to then inform business units...
As more and more partnerships between digital therapeutics and pharma companies begin to emerge, the two industries have started to size each other up. While this may foster an exchange of ideas, there is also the danger of concepts getting lost in translation between the two industries.
Yesterday DTx East in Boston pharma execs talked about the future, realities, and challenges of digital...
WebMD goes to China. WebMD is teaming up with Chinese tech giant Tencent in a deal that would introduce the health information platform to Asia. This means that WebMD’s services will be translated into Chinese and localized to suit the Chinese population.
“The agreement between WebMD and Tencent has the power to make a difference in the health of the Chinese people,” said Meng Zhang, general...
This morning, prescription digital therapeutic developer Click Therapeutics closed a $17 million funding round led by Sanofi Ventures, a subsidiary of pharma giant Sanofi.
“We’ve evaluated many companies in this space, and we believe Click Therapeutics’ mobile patient engagement platform positions the company to be a leader in the field of prescription digital therapeutics,” Bernard Davitian,...
Sanofi’s approach to digital health is broad, but focused, Rachel Sha, the company’s vice president of digital business development and licensing, told MobiHealthNews in an interview ahead of the upcoming BIO 2018 conference in Boston, where Sha will be speaking on a range of digital health-related topics.
“At Sanofi we’re lucky in the sense that we have a very clear set of digital priorities...
